Two Houston hospitals — Texas Children's Hospital and Baylor College of Medicine — have received funding from the National Institutes of Health. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

Thousands of cases of fetal growth restriction occur annually that can lead to complications at birth. In order to get a better idea of condition and to develop better monitoring technology, the National Institutes of Health has granted $3.2 million to researchers at Baylor College of Medicine and Texas Children's Hospital.

The researchers are tasked with developing "an improved way to evaluate umbilical venous blood flow using 3D and Doppler ultrasound techniques" in small fetuses, according to a release from Baylor College of Medicine.

"Our research team will initially validate the accuracy and reproducibility of new 3D volume flow measurements and then develop corresponding reference ranges in normal pregnancies," says Dr. Wesley Lee, professor of obstetrics and gynecology at Baylor, in the release.

"Detailed observations of fetal growth, heart function, and circulatory changes will be made in over 1,000 small fetuses with estimated weights below the 10th percentile," Lee continues. "The results will be correlated with pregnancy outcomes to identify prenatal predictors of clinical problems in newborns."

The grant will fund a five-year investigation collaboration between the two Houston hospitals, as well as the University of Michigan, Perinatology Research Branch of the Eunice Kennedy Shriver National Institute of Child Health, and Human Development and GE Healthcare.

FGR is a condition that affects fetuses that are below the weight normal for their gesticular age — usually in the 10th percentile of weight or less, according to Stanford Children's Health. Underlying issues with placenta or umbilical cord can increase the risks of the condition and causes of FGR can range from blood pressure problems to drug and alcohol use.

Affected fetuses can be at risk of stillbirth or neonatal death. Babies that overcome FGR complications at birth are predisposed to developmental delay and the development of adult diseases such as obesity, diabetes, coronary artery disease, and stroke, according to the release.

According to Dr. Lee, identifying these FGR and at-risk fetuses can benefit their health in infancy as well as throughout their lives.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Nominations are now open for the 2025 Houston Innovation Awards

Calling All Innovators

Calling all Houston innovators: The Houston Innovation Awards return this fall to celebrate the best and brightest in the Houston innovation ecosystem right now.

Presented by InnovationMap, the fifth annual Houston Innovation Awards will take place November 5 at TMC Helix Park.

The awards program will honor the top startups and innovators in Houston across 10 categories, and we're asking you to nominate the most deserving Houston innovators and innovative companies today.

This year's categories are:

  • Minority-founded Business, honoring an innovative startup founded or co-founded by BIPOC or LGBTQ+ representation.
  • Female-founded Business, honoring an innovative startup founded or co-founded by a woman.
  • Energy Transition Business, honoring an innovative startup providing a solution within renewables, climatetech, clean energy, alternative materials, circular economy, and beyond.
  • Health Tech Business, honoring an innovative startup within the health and medical technology sectors.
  • Deep Tech Business, honoring an innovative startup providing technology solutions based on substantial scientific or engineering challenges, including those in the AI, robotics, and space sectors.
  • Startup of the Year (People's Choice), honoring a startup celebrating a recent milestone or success. The winner will be selected by the community via an interactive voting experience.
  • Scaleup of the Year, honoring an innovative later-stage startup that's recently reached a significant milestone in company growth.
  • Incubator/Accelerator of the Year, honoring a local incubator or accelerator that is championing and fueling the growth of Houston startups.
  • Mentor of the Year, honoring an individual who dedicates their time and expertise to guide and support budding entrepreneurs.
  • Trailblazer, honoring an innovator who's made a lasting impact on the Houston innovation community.

Nominations may be made on behalf of yourself, your organization, and other leaders in the local innovation scene. The nomination period closes on August 31, so don't delay — nominate today at this link, or fill out the embedded form below.

Our panel of esteemed judges will review the nominations, and determine the finalists and winners. Finalists will be unveiled on September 30, and the 2025 Houston Innovation Awards winners will be announced live at our event on November 5.

Tickets will go on sale this fall. Stay tuned for that announcement, as well as more fanfare leading up to the 2025 Houston Innovation Awards.

Nominate now:

Interested in Innovation Awards sponsorship opportunities? Please contact sales@innovationmap.com.

MD Anderson launches $10M collaboration to advance personalized cancer treatment tech

fighting cancer

The University of Texas MD Anderson Cancer Center and Japan’s TOPPAN Holdings Inc. have announced a strategic collaboration to co-develop TOPPAN Holdings’ 3D cell culture, or organoid, technology known as invivoid.

The technology will be used as a tool for personalized cancer treatments and drug screening efforts, according to a release from MD Anderson. TOPPAN has committed $10 million over five years to advance the joint research activities.

“The strategic alliance with MD Anderson paves a promising path toward personalized cancer medicine," Hiroshi Asada, head of the Business Innovation Center at TOPPAN Holdings, said in a news release.

Invivoid is capable of establishing organoid models directly from patient biopsies or other tissues in a way that is faster and more efficient. Researchers may be able to test a variety of potential treatments in the laboratory to understand which approach may work best for the patient, if validated clinically.

“Organoids allow us to model the three-dimensional complexity of human cancers in the lab, thus allowing us to engineer a powerful translational engine—one that could not only predict how patients will respond to therapy before treatment begins but also could help to reimagine how we discover and validate next-generation therapies," Dr. Donna Hansel, division head of pathology and laboratory medicine at MD Anderson, added in the news release. “Through this collaboration, we hope to make meaningful progress in modeling cancer biology for therapeutic innovation.”

The collaboration will build upon preclinical research previously conducted by MD Anderson and TOPPAN. The organizations will work collaboratively to obtain College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certifications for the technology, which demonstrate a commitment to high-quality patient care. Once the certifications are obtained, they plan to conduct observational clinical studies and then prospective clinical studies.

“We believe our proprietary invivoid 3D cell culture technology, by enabling the rapid establishment of organoid models directly from patient biopsies, has strong potential to help identify more effective treatment options and reduce the likelihood of unnecessary therapies,” Asada added in the release. “Through collaboration on CAP/CLIA certification and clinical validation, we aim to bring this innovation closer to real-world patient care and contribute meaningfully to the advancement of cancer medicine."